Darvadstrocel is NOT FDA-approved in the United States; it is conditionally approved in the EU specifically for complex perianal fistulising Crohn's disease refractory to conventional and biologic therapy. This is the only EU-approved stem cell product for IBD. Systemic MSC induction therapy for active Crohn's or ulcerative colitis remains investigational globally; no regulatory approval has been granted. US patients seeking darvadstrocel must access it through compassionate frameworks (extremely limited) or travel to Europe.
Crohn's disease and ulcerative colitis (inflammatory bowel disease, IBD) involve chronic intestinal inflammation driven by aberrant immune responses to commensals and barrier dysfunction. Current therapies (aminosalicylates, corticosteroids, biologics) suppress inflammation but do not repair underlying mucosal defects or fully restore immune tolerance. Stem cell strategies exploit the immunoregulatory capacity of placental mesenchymal stem cells (MSCs), which secrete anti-inflammatory cytokines (IL-10, TGF-β) and promote regulatory T cell differentiation. MSCs also enhance barrier integrity by supporting tight-junction proteins and promoting mucosal healing. A particularly important development: darvadstrocel, an allogeneic MSC product, recently obtained European Union conditional approval for treatment of complex perianal Crohn's fistulae—marking the first regulatory recognition of cell therapy for IBD. Beyond this niche indication, systemic MSC therapy for induction remission and maintenance is investigational across 89 registered trials globally; thirteen actively recruit.
Am I a candidate? → · Crohn's & IBD: full overview → · Crohn's & IBD cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite